BlueWind Medical Raises $64 Million to Fund Innovative Technology for Overactive Bladder (OAB) Treatment

RENOVA iStim™ implantable tibial neuromodulation device is being studied as a minimally invasive, patient-centric solution for the treatment of OAB.

Related Keywords

United States ,Netherlands ,United Kingdom ,Israel ,Belgium ,Sweden ,Herzliya ,Tel Aviv ,Ireland ,Utah ,Americans ,American ,Sandra Muhlfeld ,Chuck Cargile ,Dan Lemaitre ,Seth Segel ,Milsomi Comorbidities ,Convatec Group Plc ,Home Services Group Of Convatec Plc ,Bluewind Medical Ltd ,American Urological Association ,Prnewswire Bluewind Medical Ltd ,Us Food Drug Administration ,Society Of Urodynamics ,Wind Medical ,Bluewind Medical ,Female Pelvic Medicine ,Urogenital Reconstruction ,Winter Meeting ,Drug Administration ,Global Continence Care ,Home Services Group ,Convatec Group ,Investigational Device Exemption ,Relations Contact ,Chief Financial ,Vice President ,Prnewswire , ,